Cell Therapeutics (CTIC +15.2%) jumps after announcing the licensing terms under which Novartis (NVS) would be able to develop and commercialize CTIC's Pixuvri cancer drug, which was recently approved by the EU. Should Novartis exercise its option on Pixuvri, the drug giant would owe CTIC a $7.5M license fee, up to $104M in milestone payments, and ongoing royalties.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs